17th International AIDS Conference Mexico City, Mexico - August 13 - 18, 2008

NEURODEVELOPMENTAL STATUS AND PRENATAL ANTIRETROVIRAL EXPOSURE IN HIV-EXPOSED UNINFECTED INFANTS

Int Conf AIDS. 2008 Aug 13-18;17 Abstract No. MOAB0102

P. Williams ¹, M. Marino², K. Malee³, L. Mofenson⁴, and the PACTG/IMPAACT 219C Team
¹Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, United States, ²Harvard School of Public Health, Department of Biostatistics, Boston, United States, ³Childrens Memorial Hospital, Northwestern University, Chicago, United States, ⁴National Institute of Child Health and Human Devevlopment, Pediatric, Adolescent and Maternal AIDS Branch, Rockville, United States

BACKGROUND: Antiretroviral (ARV) drugs are routinely provided to HIV-infected pregnant women to prevent HIV mother-to-child transmission (MTCT). While ARV use has significantly reduced MTCT to <2% in the U.S., it remains crucial to monitor for any unanticipated consequences of in utero ARV exposure on uninfected infants.

METHODS: We studied neurodevelopmental function in HIV-exposed uninfected children enrolled in PACTG 219/219C, a multi-site prospective cohort study. Cognitive and motor functioning were assessed with the Bayley Scales of Infant Development. ARV exposure information was collected during pregnancy or within the first year of life. Linear regression methods were used to evaluate the association of in utero ARV exposure on Mental Development Index (MDI) and Psychomotor Development Index (PDI) at age 2 years, controlling for potential confounders: test version (Bayley I or II); age; race; primary language; gender; primary caregiver; caregiver education level; low birth weight (LBW <2500g); geographical and urban/rural location; birth year; and maternal antenatal substance use (heroin, cocaine, stimulants).

RESULTS: Among 1840 infants born between 1993-2006, 1694 (92%) were exposed and 146 (8%) unexposed to ARV in utero. After controlling for confounders, children exposed in utero to any ARV had similar MDI and PDI scores as ARV-unexposed children (adjusted mean MDI=94.0 vs 91.6, p=0.09, PDI=93.7 vs 94.0, p=0.85). MDI scores were higher for ARV-exposed than unexposed among those with LBW (adjusted mean=91.9 vs 82.5, p=0.01). Maternal antenatal substance use was reported for 17% of mothers, but was not associated with MDI or PDI scores. All other covariates showed significant associations with MDI scores except primary caregiver,and with PDI scores except race and primary language.

CONCLUSIONS: No decline in cognitive or motor function was observed for infants with in utero ARV exposure compared to unexposed. While these results are reassuring, continued evaluation of uninfected infants with in utero ARV exposure for late outcomes is important.

Download PDF of this abstract.

2008-08-13
MOAB0102

Copyright © 2008 - International AIDS Society (IAS). All information and content relating to the abstracts from the 16th International AIDS Conference, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is a 501c(3) not-for-profit organization made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, GlaxoSmithKline, the National Library of Medicine, Roche / Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.